We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

64 hedge funds and large institutions have $639M invested in Aprea Therapeutics in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

36% more capital invested

Capital invested by funds: $468M → $639M (+$171M)

28% more funds holding

Funds holding: 50 → 64 (+14)

0.71% more ownership

Funds ownership: 3.2% → 3.91% (+0.71%)

Holders
64
Holders Change
+14
Holders Change %
+28%
% of All Funds
1.31%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
22
Increased
25
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
+$60.8M
2
CCM
Consonance Capital Management
New York
+$41.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$11M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.3M
5
SFM
Sphera Funds Management
Israel
+$5.19M

Top Sellers

Rank Fund Capital Flow
1
5VM
5AM Venture Management
California
-$21M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$18.2M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$9.17M
4
EI
EAM Investors
California
-$2.37M
5
EGI
EAM Global Investors
California
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.24M +$343K +522 +49%
AA
27
ALPS Advisors
Colorado
$1.11M -$310K -472 -25%
Goldman Sachs
28
Goldman Sachs
New York
$1.05M +$489K +745 +123%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.03M -$377K -574 -30%
Victory Capital Management
30
Victory Capital Management
Texas
$840K -$749K -1,141 -51%
Swiss National Bank
31
Swiss National Bank
Switzerland
$822K +$696K +1,060 New
Millennium Management
32
Millennium Management
New York
$788K +$667K +1,016 New
TD Asset Management
33
TD Asset Management
Ontario, Canada
$662K +$560K +854 New
AllianceBernstein
34
AllianceBernstein
Tennessee
$640K +$302K +460 +126%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$619K +$524K +798 New
SFI
36
Susquehanna Fundamental Investments
Pennsylvania
$496K +$420K +640 New
SAMH
37
Shanda Asset Management Holdings
British Virgin Islands
$460K +$389K +593 New
Wells Fargo
38
Wells Fargo
California
$451K +$152K +232 +66%
VEA
39
Virtus ETF Advisers
New York
$443K +$375K +572 New
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$420K +$33.5K +51 +10%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$388K – – –
SSA
42
Schonfeld Strategic Advisors
New York
$334K +$282K +430 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$326K +$85.3K +130 +45%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$309K +$52.5K +80 +25%
CCM
45
CAAS Capital Management
New York
$235K +$199K +303 New
AI
46
Atom Investors
Texas
$221K +$186K +284 New
AIG
47
American International Group
New York
$171K +$19K +29 +15%
Deutsche Bank
48
Deutsche Bank
Germany
$136K +$42K +64 +57%
UBS Group
49
UBS Group
Switzerland
$123K -$39.4K -60 -27%
MIM
50
MetLife Investment Management
New Jersey
$122K – – –
1
2
3

APRE Hedge Fund Activity: Q2 2020 in Review

64 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2020, worth a combined $639M — up 36% from $468M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new APRE positions and 8 closed out — a net gain of 14 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $60.8M. The largest seller was 5AM Venture Management, cutting an estimated $21M.

  • 64 institutional investors held Aprea Therapeutics (APRE) as of Q2 2020, up from 50 in Q1 2020.
  • Funds reported $639M of Aprea Therapeutics stock for Q2 2020, up 36% quarter-over-quarter.
  • 22 funds opened new Aprea Therapeutics positions in Q2 2020 and 8 closed out, a net change of +14 holders.
  • The largest Aprea Therapeutics buyer in Q2 2020 was Versant Venture Management, an estimated $60.8M added.
  • The largest Aprea Therapeutics seller in Q2 2020 was 5AM Venture Management, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2020.